WAT Waters Corporation
Wonderful razor-blade franchise in analytical instruments, but priced for growth it hasn't shown in a decade.
The business
Waters makes high-precision liquid chromatography (LC) and mass spectrometry (MS) instruments plus TA Instruments' thermal/rheological analysis systems, sold mainly to pharma, biotech, and industrial/food-safety labs. The real economic engine is the razor/razorblade model: instruments are the razor, and highly recurring consumables, columns, service contracts, and software drive the bulk of profit.
Quality gate · 85/100
Moat & management
| Moat | wide moat |
| Source | switching costs |
| Trajectory | stable |
| Management | adequate |
Once an LC-MS method is validated and embedded in a regulated pharma QC/QA workflow, ripping it out means re-validating with regulators (FDA/EMA) — a costly, multi-year process labs avoid. This locks in decades of consumables and service revenue, evidenced by 20%+ median ROIC and 55% gross margins sustained across cycles.
Balance sheet is conservative (net debt/EBITDA ~0.9x) and share count is essentially flat, showing no reckless dilution or empire-building, but FCF conversion of 0.77 and anemic 2.1% 5y revenue CAGR suggest capital allocation has been more custodial than value-accretive.
Owner-earnings inputs
| Owner earnings (TTM) | 263.81M |
| Owner-earnings yield | 0.7% |
| Free-cash-flow yield | 0.7% |
| Growth used (normalized) | 7.0% |
| Market-implied growth (reverse DCF) | 25.0% |
| Terminal growth | 3.0% |
| Discount rate (hurdle) | 10.2% |
Projected owner earnings
| Yr | Owner earnings | Growth | PV |
|---|---|---|---|
| 1 | 282.28M | 7.0% | 256.26M |
| 2 | 301.23M | 6.7% | 248.25M |
| 3 | 320.59M | 6.4% | 239.86M |
| 4 | 340.29M | 6.1% | 231.12M |
| 5 | 360.22M | 5.9% | 222.11M |
| 6 | 380.29M | 5.6% | 212.87M |
| 7 | 400.39M | 5.3% | 203.46M |
| 8 | 420.41M | 5.0% | 193.94M |
| 9 | 440.23M | 4.7% | 184.36M |
| 10 | 459.72M | 4.4% | 174.78M |
| 11 | 478.77M | 4.1% | 165.24M |
| 12 | 497.24M | 3.9% | 155.80M |
| 13 | 514.99M | 3.6% | 146.49M |
| 14 | 531.92M | 3.3% | 137.35M |
| 15 | 547.87M | 3.0% | 128.43M |
Key risks
- Pharma capex cycles: post-COVID biotech/pharma instrument-buying slowdown has suppressed volumes and could persist
- China exposure: a meaningful revenue base there faces both macro softness and geopolitical/tariff risk
- Academic/government funding pressure (esp. NIH) could dent a portion of end-market demand
- Currency and administration policy risk given multinational pharma/biotech customer base
Catalysts
- Recurring consumables/service mix continuing to rise as a share of revenue, smoothing cycles
- Eventual normalization of pharma/biotech instrument capex after a multi-year pause
- New high-value MS platforms (e.g., mass spec expansion) gaining share in a duopoly/oligopoly market
Recent news
score · 8 articles
- Waters (WAT) Earnings Expected to Grow: Should You Buy?
- Will Waters (WAT) Beat Estimates Again in Its Next Earnings Report?
- Waters (WAT) After Recurring Revenue Strength, Is The Valuation Still Compelling?
- 1 S&P 500 Stock to Consider Right Now and 2 That Underwhelm
- IQVIA Gears Up to Report Q2 Earnings: What's in the Offing?
- Q1 Research Tools & Consumables Earnings Review: First Prize Goes to Waters Corporation (NYSE:WAT)
- Waters Corporation's Quarterly Earnings Preview: What You Need to Know
- 2 Large-Cap Stocks to Keep an Eye On and 1 We Ignore
⚠ maintenance capex ≈ min(capex, D&A), capped at FCF · Price pays for ~25%/yr owner-earnings growth over 15y (reverse DCF); model credits 7%. · Rich vs our conservative value, but a quality business is not a short — stance is WAIT for a better price, not sell.